Atenolol (Tenormin) is a cardioselective beta-1 adrenergic blocker used for hypertension, angina pectoris, and secondary prevention after myocardial infarction. Unlike non-selective beta-blockers such as propranolol, atenolol's selectivity for cardiac beta-1 receptors at therapeutic doses reduces (though does not eliminate) bronchospasm risk in patients with asthma or COPD. A critical distinction from metoprolol: atenolol is renally excreted unchanged, requiring dose adjustment in kidney disease. Abrupt discontinuation can cause dangerous rebound hypertension and angina — always taper gradually.
Atenolol
Uses & FDA Indications
Atenolol is FDA-approved for hypertension (alone or in combination with other antihypertensives), angina pectoris (stable angina), and acute myocardial infarction (to reduce cardiovascular mortality in hemodynamically stable patients). It is one of the most commonly prescribed beta-blockers worldwide, though newer beta-blockers with additional evidence for heart failure outcomes (metoprolol succinate, carvedilol, bisoprolol) are preferred in certain populations.
Off-label uses include rate control in atrial fibrillation and flutter, migraine prophylaxis, performance anxiety (situational anxiety triggered by stress or performance situations), hyperthyroidism symptom management, and essential tremor.
A clinically important limitation: atenolol has not demonstrated the mortality benefit in heart failure with reduced ejection fraction (HFrEF) that metoprolol succinate, carvedilol, and bisoprolol have. For patients with heart failure, guideline-directed therapy mandates one of those three agents — atenolol is not an appropriate substitute.
How It Works
Atenolol competitively blocks beta-1 adrenergic receptors in the heart and kidneys. Cardiac beta-1 blockade produces a constellation of effects that lower blood pressure and cardiac workload: reduced heart rate (negative chronotropy), reduced force of cardiac contraction (negative inotropy), and reduced conduction velocity through the AV node (negative dromotropy). Together, these effects lower cardiac output and myocardial oxygen demand.
In the kidneys, beta-1 blockade reduces renin release from juxtaglomerular cells, thereby reducing angiotensin II production and aldosterone secretion — contributing to blood pressure lowering through the renin-angiotensin-aldosterone system (RAAS). The antihypertensive effect of atenolol thus combines reduced cardiac output with reduced RAAS activation.
Cardioselectivity means atenolol preferentially blocks beta-1 receptors over beta-2 receptors at standard therapeutic doses. Beta-2 receptors mediate bronchodilation in the lungs and vasodilation in peripheral vessels. However, cardioselectivity is dose-dependent and relative — at higher doses, atenolol loses selectivity and will also block beta-2 receptors. In patients with reactive airway disease (asthma, COPD), even cardioselective beta-blockers should be used cautiously and only when the cardiovascular benefit clearly outweighs the risk of bronchospasm.
Side Effects
Common
- Bradycardia — reduced heart rate is an expected pharmacological effect; problematic if symptomatic (fatigue, dizziness, syncope)
- Fatigue and exercise intolerance — very common; results from reduced cardiac output response to physical exertion; may limit athletic performance
- Cold extremities — reduced peripheral circulation; Raynaud's phenomenon can worsen
- Hypotension and dizziness — particularly with position changes (orthostatic)
- Depression — reported with beta-blockers; atenolol's limited CNS penetration theoretically reduces this risk vs. propranolol, though clinical evidence is mixed
- Sexual dysfunction — reduced libido and erectile dysfunction
Serious
- Bronchospasm — even cardioselective beta-blockers can trigger bronchoconstriction in susceptible patients, particularly at higher doses; potentially life-threatening in severe asthma
- AV block — slowing of AV nodal conduction can progress to heart block; risk elevated with concurrent calcium channel blockers (diltiazem, verapamil)
- Hypoglycemia masking — beta-blockers blunt tachycardia and tremor (sympathetic warning signs of hypoglycemia) in diabetic patients on insulin or sulfonylureas; diaphoresis is preserved as a hypoglycemia warning sign
- Rebound withdrawal syndrome — abrupt discontinuation causes dangerous catecholamine surge; see Warnings section
- Heart failure exacerbation — atenolol is not indicated for heart failure and can acutely worsen decompensated HF
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Non-dihydropyridine CCBs (diltiazem, verapamil) | Additive cardiac conduction slowing and negative inotropy. Combination can cause severe bradycardia, AV block, or acute heart failure. Both drug classes slow AV node conduction through different mechanisms. | High — avoid combination; if necessary, monitor with great caution and at low doses |
| Antiarrhythmics (amiodarone, digoxin, class I agents) | Additive bradycardia and AV conduction slowing. Amiodarone + beta-blocker combinations require careful monitoring for symptomatic bradycardia and heart block. | Moderate-High — monitor heart rate and ECG |
| Alpha-1 blockers (prazosin, tamsulosin, doxazosin) | Enhanced first-dose hypotension effect. Beta-blockade prevents reflex tachycardia that normally mitigates the hypotensive effect of the first alpha-blocker dose. | Moderate — warn patients about fall/syncope risk; initiate alpha-blocker at lowest dose |
| Insulin and Sulfonylureas | Atenolol masks sympathetic warning signs of hypoglycemia (tachycardia, tremor) while potentially prolonging hypoglycemia. Sweating is preserved. Risk of undetected severe hypoglycemia. | Moderate — counsel diabetic patients; monitor blood glucose; educate on preserved vs. masked hypoglycemia symptoms |
| Clonidine | Risk of rebound hypertension if clonidine is discontinued while on a beta-blocker. Beta-blockade leaves alpha-2 agonist withdrawal unopposed, causing catecholamine surge. Atenolol should be discontinued several days before stopping clonidine. | Moderate-High — taper clonidine first, then taper beta-blocker |
| NSAIDs (ibuprofen, naproxen, indomethacin) | NSAIDs can blunt the antihypertensive effect of beta-blockers through prostaglandin-mediated sodium retention and vasoconstriction. | Moderate — monitor blood pressure; minimize NSAID use in hypertensive patients |
Warnings & Contraindications
Contraindications
- Sinus bradycardia (heart rate consistently below 60 bpm without pacemaker)
- Greater than first-degree heart block (without pacemaker)
- Cardiogenic shock
- Decompensated heart failure
- Severe reactive airway disease (asthma) — relative contraindication; absolute in severe, poorly controlled asthma
- Hypersensitivity to atenolol
Abrupt Discontinuation Warning
Stopping atenolol suddenly after long-term use carries serious cardiovascular risk. During beta-blocker therapy, the heart upregulates (increases the number and sensitivity of) beta-adrenergic receptors. When the blocker is abruptly withdrawn, catecholamines — which remain at normal levels — stimulate a now-hypersensitive receptor population, producing a dangerous rebound: tachycardia, hypertension, increased angina, and potentially myocardial infarction or fatal arrhythmia in patients with coronary artery disease. Atenolol should be tapered over 1–2 weeks, not stopped suddenly. During tapering, patients should minimize physical exertion. If the drug must be stopped urgently, observe the patient carefully.
Renal Impairment Dosing
Atenolol is unique among commonly used beta-blockers in that it is eliminated almost entirely by the kidneys unchanged — it undergoes minimal hepatic metabolism. In patients with chronic kidney disease or acute kidney injury, atenolol accumulates to higher plasma levels than intended, increasing the risk of bradycardia, hypotension, AV block, and other adverse effects. Dose adjustment based on creatinine clearance is required. This contrasts with metoprolol, which is hepatically metabolized and does not require renal dose adjustment.
Check for atenolol interactions with calcium channel blockers, diabetes medications, and other drugs.
Check Drug Interactions →Frequently Asked Questions
Why shouldn't you stop atenolol suddenly?
Abrupt discontinuation of atenolol and other beta-blockers after long-term use can cause a withdrawal syndrome characterized by rebound hypertension, tachycardia, palpitations, angina, and in patients with coronary artery disease, potentially myocardial infarction or severe cardiac arrhythmias. This occurs because beta-adrenergic receptors upregulate (increase in number and sensitivity) during chronic beta-blockade. When the blocker is suddenly removed, the now-hypersensitive receptors are flooded with normal levels of catecholamines, producing an exaggerated sympathetic response. Atenolol should always be tapered gradually over 1–2 weeks under medical supervision when discontinuation is necessary.
Is atenolol safe in kidney disease?
Atenolol requires careful dose adjustment in kidney disease because it is excreted almost entirely unchanged by the kidneys — unlike metoprolol, which is hepatically metabolized. In patients with reduced kidney function (low GFR), atenolol accumulates to higher-than-intended plasma levels, causing excessive bradycardia, hypotension, and other adverse effects. Prescribers must calculate creatinine clearance and reduce the dose frequency accordingly in patients with renal impairment. Patients on dialysis are also affected. This renal dependence is a key pharmacokinetic distinction from metoprolol succinate or tartrate.
What is the difference between atenolol and metoprolol?
Both atenolol and metoprolol are cardioselective (beta-1 selective) beta-blockers, but they differ in several clinically important ways. Metoprolol is hepatically metabolized (primarily by CYP2D6), making it less affected by kidney function but subject to CYP2D6 drug interactions and genetic variability in metabolism. Atenolol is renally excreted unchanged, requiring dose adjustments in kidney disease but without significant metabolic drug interactions. Metoprolol succinate (Toprol XL) is extended-release and preferred for heart failure (proven mortality benefit in HFrEF — atenolol does not have this indication). Metoprolol also crosses the blood-brain barrier more readily than atenolol, which may contribute to more CNS side effects (fatigue, depression) but also to its use for migraine prevention.